Recombinant Vaccines Market Size, Share, And Growth Report 2032

Recombinant Vaccines Market: Size

The global Recombinant Vaccines Market size was worth around USD 10.15 billion in 2023 and is predicted to grow to around USD 26.61 billion by 2032 with a compound annual growth rate (CAGR) of roughly 11.3% between 2024 and 2032.

The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Recombinant Vaccines Market on a global and regional level.

Request Free Sample

Recombinant Vaccines Market: Overview

A vaccine is a biological product that offers active attained immunity against a specific disease. A recombinant vaccine is manufactured via recombinant DNA (rDNA) technology. This includes introducing the DNA (Deoxyribonucleic Acid) encoding an antigen, which encourages an immune reaction into mammalian or bacterial cells, by articulating the antigen in these cells and then refining it from them.

The safe to use nature of recombinant vaccines, high investments by recombinant vaccine manufacturers for novel products’ development, rising government initiatives to boost the recombinant vaccines usage, increasing augmented and viable healthcare demand, simplified applications of recombinant vaccines, and growing accessibility of recombinant vaccines via conventional supply chains, escalating number of regulatory authorizations, and growing infectious diseases occurrence are driving the recombinant vaccines market globally. The rising awareness regarding recombinant vaccines benefits in developing regions, increasing per capita healthcare expenditure, growing demand for veterinary recombinant vaccines, and ongoing technological improvements in recombinant vaccines will create additional opportunities for the recombinant vaccines market in the years ahead. However, risks related to the use of attenuated vaccines, high cost of recombinant vaccines, and the lack of appropriate healthcare setup and trained physicians in developing regions will restrict the global recombinant vaccines market development.

Request Free Sample

Recombinant Vaccines Market: Segmentation

The study provides a decisive view of the recombinant vaccines market by segmenting the market based on type, application, disease, distribution channel, and region.

Based on type, the recombinant vaccines market includes attenuated, vector, and subunit. The subunit segment accounted for the highest market share in 2023.

The application segment includes veterinary and human. The human segment accounted for the highest market share in 2023. The disease segment comprises hepatitis B, cancer, influenza, and others. The hepatitis B segment is expected to register the highest CAGR over the estimated time period.

The distribution channel segment is fragmented into hospitals, clinics, veterinary clinics, retail pharmacies, and others.

Recombinant Vaccines Market: Report Scope

Recombinant Vaccines Market: Regional Analysis

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

North America will lead the global recombinant vaccines market in the future, owing to rising developments in the field of genetic engineering and molecular biology, increasing transmittable diseases prevalence, huge research and development expenditure by major manufacturers, high vaccination rate, and rapid uptake of techniques like rDNA technology. Europe will hold the second spot in this global market, due to the presence of latest treatment facilities, high healthcare expenditure, rising infectious disorders incidences, escalating cancer rate, and growing availability of latest healthcare infrastructure. The Asia Pacific will grow rapidly over the forecast period, owing to the rising government initiatives governments to increase vaccination rate, an enormous patient pool, increasing investments by domestic and global manufacturers, escalating need for large quantities of vaccines, and ongoing R&D.

Recombinant Vaccines Market: Competitive Players

Some key players of the global recombinant vaccines market are

• Pfizer
• Merck
• Sanofi Pasteur
• Bayer
• GlaxoSmithKline
• Serum Institute of India
• Abiomed
• Johnson & Johnson
• Emergent Bio Solutions
• Mitsubishi Tanabe Pharma.

The Global Recombinant Vaccines Market is segmented as follows:

By Type Analysis

• Attenuated
• Vector
• Subunit

By Application Analysis

• Veterinary
• Human

By Disease Analysis

• Hepatitis B
• Cancer
• Influenza
• Others

By Distribution Channel Analysis

• Hospitals
• Clinics
• Veterinary Clinics
• Retail Pharmacies
• Others

By Region Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa